Portfolio News

Our Portfolio Companies

Our portfolio companies are enabling the future of biotechnology, cell and gene therapies, vaccines and regenerative medicine. 

The Future of Pathology

Alpenglow Biosciences reimagines pathology by providing a full-stack solution to nondestructively image large tissues in 3D at sub-cellular resolution. Its novel chemistry, patented high-throughput light-sheet microscope, and cloud-based AI analysis software adds a new dimension to pathology

Combining coding and biology to provide human cells for research, drug discovery, and cell therapy

Biomedical innovation and a new generation of cures through precision engineered human cells. bit.bio combines the concepts of coding and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines.

Revolutionizing analytical testing For the benefit of people’s health

Bionter AG addresses a challenge faced by the biopharmaceutical industry, minimizing the amount of costly sample required to determine particle count as part of analysis. The device reduces the overall sample volume required, saving material for other analytical endpoints, hence reducing costs. Its smart automated workflow drives efficiency, minimizes human interaction and therefore improving reliability, data integrity and in turn patient safety.

DELIVERY OF GENE EDITING PAYLOADS FOR CELL AND GENE THERAPIES

CellFE Biotech is enabling the next generation of cell and gene therapies by efficiently delivering gene-editing payloads with high throughput, and preserving cell function and viability.

Integrating Human Cells, Systems, and Data

Curi Bio’s preclinical discovery platform combines human stem cells, systems, and data to accelerate the discovery of new medicines. The Curi Engine is a seamless, bioengineered platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and A.I./M.L.-enabled phenotypic screening data.

RNA SPLICING ANALYTICS + ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY

Envisagenics' mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence.

REAL-TIME CELL ANALYSIS

The RESIPHER series of cell culture monitors are the world's first handheld devices to measure oxygen consumption in standard multi-well plates, providing continuous insight directly from your incubator.

ACCELERATING THE USE OF STEM CELLS FOR REGENERATIVE MEDICINE

RoosterBio is accelerating the field of regenerative medicine and disrupting the market by radically simplifying human mesenchymal stem / stromal cell (hMSC) biomanufacturing and supply of critical reagents.

Robust, cost-efficient production processes for recombinant proteins

Superior technologies and solutions for the production of recombinant proteins in E. coli and other bacteria through a combination of experienced life science researchers, state-of-the-art laboratory facilities, a proprietary technology platform and skillful management.

High purity mRNA from concept to clinical trials

Vernal Biosciences provides mRNA and LNP-mRNA manufacturing services to democratize the use of mRNA for all use cases ranging from drug discovery to clinical development across all use cases such as gene editing and regulation, cellular programming, vaccines, mRNA replacement, oncology, autoimmune, and protein degradation.

MANUFACTURING SOLUTIONS FOR INCREASING EFFICIENCIES OF VIRAL-BASED THERAPIES, CELL THERAPIES AND VACCINE CANDIDATES.

Virica Biotech’s Viral Sensitizer (VSE™) platform reduces production inefficiencies caused by innate anti-viral defenses in manufacturing cells. Customizable solutions substantially increase manufacturing yields and reduce the cost of goods for a range of products, including vaccines, cell and gene therapies, and anti-cancer therapies.

Hardware and AI-driven Software for Drug Screening and Primary Cell Analysis

Xcell Bioscience’s mission is to enhance the performance and safety of cell and gene-based therapies through the design and development of revolutionary technology platforms. The Avatar AI and Avatar instruments along with AI-driven software allow researchers to discover novel insights into immune and tumor biology and enable the translation of these insights at patient scale through the development of its pioneering cell therapy manufacturing platform. 

Exits

ACOUSTIC CELL HANDLING

ACQUIRED by MilliporeSigma, October 2019